Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells
Open Access
- 20 July 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 89 (4) , 368-377
Abstract
An elevation in the circulating level of the squamous‐cell carcinoma antigen (SCCA) can be a poor prognostic indicator in certain types of squamous‐cell cancers. Total SCCA in the circulation comprises 2 nearly identical, ∼45 kDa proteins, SCCA1 and SCCA2. Both proteins are members of the high‐molecular weight serine proteinase inhibitor (serpin) family with SCCA1 paradoxically inhibiting lysosomal cysteine proteinases and SCCA2 inhibiting chymotrypsin‐like serine proteinases. Although SCCA1 and SCCA2 are detected in the cytoplasm of normal squamous epithelial cells, neither serpin is detected normally in the serum. Thus, their presence in the circulation at relatively high concentrations suggests that malignant epithelial cells are re‐directing serpin activity to the fluid phase via an active secretory process. Because serpins typically inhibit their targets by binding at 1:1 stoichiometry, a change in the distribution pattern of SCCA1 and SCCA2 (i.e., intracellular to extracellular) could indicate the need of tumor cells to neutralize harmful extracellular proteinases. The purpose of our study was to determine experimentally the fate of SCCA1 and SCCA2 in squamous carcinoma cells. Using subcellular fractionation, SCCA‐green fluorescent fusion protein expression and confocal microscopy, SCCA1 and SCCA2 were found exclusively in the cytosol and were not associated with nuclei, mitochondria, lysosomes, microtubules, actin or the Golgi. In contrast to previous reports, metabolic labeling and pulse‐chase experiments showed that neither non‐stimulated nor TNFα/PMA‐stimulated squamous carcinoma cells appreciably secreted these ov‐serpins into the medium. Collectively, these data suggest that the major site of SCCA1 and SCCA2 inhibitory activity remains within the cytosol and that their presence in the sera of patients with advanced squamous‐cell carcinomas may be due to their passive release into the circulation. Int. J. Cancer 89:368–377, 2000.Keywords
This publication has 51 references indexed in Scilit:
- A Cytosolic Granzyme B Inhibitor Related to the Viral Apoptotic Regulator Cytokine Response Modifier A Is Present in Cytotoxic LymphocytesJournal of Biological Chemistry, 1996
- Proteases in apoptosisCellular and Molecular Life Sciences, 1996
- Proteinase Inhibitor 6 Cannot Be Secreted, Which Suggests It Is a New Type of Cellular SerpinJournal of Biological Chemistry, 1996
- GFP in mammalian cellsTrends in Genetics, 1995
- The ovalbumin family of serpin proteinsFEBS Letters, 1993
- Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervixGynecologic Oncology, 1990
- Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes.Journal of Experimental Medicine, 1988
- Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial Determinations and Tissue LocalizationCancer, 1985
- Segregation of mutant ovalbumins and ovalbumin-globin fusion proteins in Xenopus oocytesJournal of Molecular Biology, 1984
- A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha1-proteinase inhibitorBiochemical and Biophysical Research Communications, 1980